Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial. Worldwide trends in locoregional therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback